Moderna to test a “multivalent” COVID vaccine as well as single-valent boosters

By on .

By Daniel R. Lucey MD, MPH, FIDSA

On Wednesday (Feb. 24) Moderna announced a new vaccine strategy against the variant B.1.351 (501Y.V2) now predominant in several nations in southern Africa, and identified in more than 40 nations, as well as multiple U.S. states. Part of this strategy is the first-ever “multivalent” vaccine candidate that “combines mRNA-1273, Moderna’s authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at the 50 µg dose level and lower.”

As advocated here Jan. 31, multivalent vaccines should be developed against multivariant viruses to prevent re-infections, more variants and a prolonged pandemic.

Also on this IDSA Science Speaks site Dec. 22, a rationale was presented for concern regarding antibody-evasion by this variant B.1.351 (501Y.V2) first found in South Africa, due to Spike protein mutations E484K and K417N.

Of note, however, the updated guidance for COVID-19 vaccines from the FDA Feb. 22 focusing on virus variants in appendix 2 explicitly pertained to single-valent booster candidate vaccines.  On page 18 of 21 of this guidance, FDA stated (my boldtype added): “This document also does not address considerations for multivalent COVID-19 vaccines”.  Thus, further FDA guidance on multivalent vaccine candidates is anticipated.

Moderna reported multivalent booster candidate as only one of its three approaches:

  • “A variant-specific booster candidate, mRNA-1273.351, based on the B.1.351 variant first identified in the Republic of South Africa, at the 50 µg dose level and lower.
  • A multivalent booster candidate, mRNA-1273.211, which combines mRNA-1273, Moderna’s authorized vaccine against ancestral strains, and mRNA-1273.351 in a single vaccine at the 50 µg dose level and lower.
  • A third dose of mRNA-1273, the Moderna COVID-19 Vaccine, as a booster at the 50 µg dose level. The Company has already begun dosing this cohort with the booster.”

Dr. Daniel Lucey

Daniel Lucey, M.D. MPH, FIDSA, FACP, is a Clinical Professor of Medicine at Dartmouth Geisel School of Medicine, Infectious Disease adjunct Professor at Georgetown Medical Center, senior scholar at Georgetown Law, Anthropology Research Associate at the Smithsonian Museum of Natural History and a member of the Infectious Diseases Society of America Global Health Committee. He served as a volunteer to outbreaks overseas including hands-on Ebola patient care in Sierra Leone and Liberia (Doctors without Borders) 2014, MERS 2013, SARS 2003, as well as HIV, H5N1, Zika, yellow Fever, and pneumonic plague 2017 (with WHO/USAID/CDC).  Since Jan. 6, 2020 he has contributed over 75 posts to Science Speaks on COVID-19 and traveled to China in February 2020. He initially proposed, then fundraised and helped design the content for 2018-2022 Smithsonian Exhibition on Epidemics due to zoonotic viruses. From 1982-1988 he trained at University of California San Francisco and Harvard and was an attending physician at the NIH (NIAID) in the 1990s while in the US Public Health Service.

2 thoughts on “Moderna to test a “multivalent” COVID vaccine as well as single-valent boosters

  1. Kathryn Love M.D.

    I wish Pfizer/BioNTech were closer behind than it seems they are as I anticipate that the Moderna booster or multivalent will be offered only to prior Moderna recipients

    Reply
  2. Pingback: First multivalent vaccine with a variant (B.1.351) begins: Will it protect against other E484K variants? | Science Speaks: Global ID News

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.